PharmaCell has entered into an agreement with Dendreon Corp. for the commercial manufacture of Dendreon’s recently approved cellular immunotherapy product Provenge dispersion for infusion. Provenge was granted marketing authorization in the EU for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer in adults where chemotherapy is not yet indicated. Provenge was approved in the U.S. in 2010 and is produced by Dendreon at its own manufacturing facil...